| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Gärde, G J Matheson, K Varnäs, P Svenningsson, E Hedman-Lagerlöf, J Lundberg, L Farde, M Tige. Altered serotonin 1B receptor binding after escitalopram for depression is correlated with treatment effect. The international journal of neuropsychopharmacology. 2024-05-02. PMID:38695786. |
major depressive disorder (mdd) is commonly treated with selective serotonin reuptake inhibitors (ssris). |
2024-05-02 |
2024-05-04 |
human |
| Shampa Maji, Debadatta Mohapatra, Monalisa Jena, Anand Srinivasan, Rituparna Mait. Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol. BMJ open. vol 14. issue 4. 2024-04-30. PMID:38688675. |
the present randomised controlled trial has been planned to evaluate the efficacy and safety of add-on dextromethorphan to selective serotonin reuptake inhibitors (ssris) in major depressive disorder (mdd). |
2024-04-30 |
2024-05-03 |
Not clear |
| Deniz Bozdag, Jeroen van Voorthuizen, Nikita Korpel, Sander Lentz, Hande Gurer-Orhan, Jorke H Kamstr. Dysregulation of adipogenesis and disrupted lipid metabolism by the antidepressants citalopram and sertraline. Toxicology and applied pharmacology. 2024-04-21. PMID:38643950. |
selective serotonin reuptake inhibitors (ssris) are widely used medications for the treatment of major depressive disorder. |
2024-04-21 |
2024-04-24 |
human |
| Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, Marina Belenky, Vasant R Marur, A John Rush, W Edward Craighead, Helen S Mayberg, Boadie W Dunlop, Bruce S Kristal, Rima Kaddurah-Daou. Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder. medRxiv : the preprint server for health sciences. 2024-04-18. PMID:38633777. |
metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive behavior therapy on key neurotransmitter pathways in major depressive disorder. |
2024-04-18 |
2024-04-20 |
Not clear |
| Granville J Matheson, Francesca Zanderigo, Jeffrey M Miller, Elizabeth A Bartlett, J John Mann, R Todd Ogde. PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [ bioRxiv : the preprint server for biology. 2024-04-01. PMID:38559101. |
pet imaging of the serotonin 1a receptor in major depressive disorder: hierarchical multivariate analysis of [ the serotonin 1a receptor has been linked to both the pathophysiology of major depressive disorder (mdd) and the antidepressant action of serotonin reuptake inhibitors. |
2024-04-01 |
2024-04-04 |
Not clear |
| Evyn M Peters, Orhan Yilmaz, Cindy Li, Lloyd Balbuen. Interpersonal sensitivity and response to selective serotonin reuptake inhibitors in patients with acute major depressive disorder. Journal of affective disorders. 2024-03-27. PMID:38537756. |
interpersonal sensitivity and response to selective serotonin reuptake inhibitors in patients with acute major depressive disorder. |
2024-03-27 |
2024-03-30 |
Not clear |
| Marcin Siwek, Adrian Andrzej Chrobak, Anna Julia Krupa, Aleksandra Gorostowicz, Adrian Gerlich, Andrzej Juryk, Dominika Dude. TED (Trazodone Effectiveness in Depression): effectiveness of trazodone extended-release in subjects with unsatisfactory response to SSRIs. Psychiatria polska. 2024-03-14. PMID:38484384. |
selective serotonin reuptake inhibitors (ssris) are the most commonly used drugs to treat major depressive disorder (mdd). |
2024-03-14 |
2024-03-17 |
human |
| Svetlana Adonina, Ekaterina Bazhenova, Darya Bazovkin. Effect of Short Photoperiod on Behavior and Brain Plasticity in Mice Differing in Predisposition to Catalepsy: The Role of BDNF and Serotonin System. International journal of molecular sciences. vol 25. issue 5. 2024-03-13. PMID:38473717. |
both the neurotransmitter serotonin (5-ht) and brain-derived neurotrophic factor (bdnf) are involved in the pathophysiological mechanisms underlying catalepsy and depressive disorders. |
2024-03-13 |
2024-03-15 |
mouse |
| Svenja Bremshey, Juliana Groß, Kim Renken, Olivia Andrea Massec. The role of serotonin in depression-A historical roundup and future directions. Journal of neurochemistry. 2024-03-13. PMID:38477031. |
in the late 1960s, the serotonin hypothesis was published, suggesting that serotonin is the key player in depressive disorders. |
2024-03-13 |
2024-03-15 |
Not clear |
| Giovanni Ostuzzi, Chiara Gastaldon, Mauro Tettamanti, Massimo Cartabia, Igor Monti, Andrea Aguglia, Eugenio Aguglia, Francesco Bartoli, Camilla Callegari, Andrea Canozzi, Elvira Anna Carbone, Giuseppe Carrà, Rosangela Caruso, Simone Cavallotti, Stefania Chiappini, Fabrizio Colasante, Beatrice Compri, Armando D'Agostino, Pasquale De Fazio, Renato de Filippis, Matteo Gari, Marta Ielmini, Gianmarco Ingrosso, Silvia Mammarella, Giovanni Martinotti, Alessandro Rodolico, Rita Roncone, Enrico Sterzi, Lorenzo Tarsitani, Elisa Tiberto, Liliana Todini, Francesco Amaddeo, Barbara D'Avanzo, Angelo Barbato, Corrado Barbu. Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. EClinicalMedicine. vol 69. 2024-02-22. PMID:38384338. |
tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (vespa): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. |
2024-02-22 |
2024-02-24 |
Not clear |
| Seyed Morteza Mirjebreili, Reza Shalbaf, Ahmad Shalba. Prediction of treatment response in major depressive disorder using a hybrid of convolutional recurrent deep neural networks and effective connectivity based on EEG signal. Physical and engineering sciences in medicine. 2024-02-15. PMID:38358619. |
in this study, we have developed a novel method based on deep learning and brain effective connectivity to classify responders and non-responders to selective serotonin reuptake inhibitors (ssris) antidepressants in major depressive disorder (mdd) patients prior to the treatment using eeg signal. |
2024-02-15 |
2024-02-17 |
Not clear |
| Małgorzata Honorata Janas-Kozik, Agnieszka Słopień, Barbara Remberk, Marcin Siwe. The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 1 - Clinical efficacy and areas of application. Psychiatria polska. vol 57. issue 5. 2024-02-13. PMID:38345118. |
the place of selective serotonin reuptake inhibitors (ssris) in the treatment of depressive disorders in children and adolescents. |
2024-02-13 |
2024-02-15 |
Not clear |
| Małgorzata Honorata Janas-Kozik, Agnieszka Słopień, Barbara Remberk, Marcin Siwe. The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2 - pharmacological properties and safety of use. Psychiatria polska. vol 57. issue 5. 2024-02-13. PMID:38345119. |
the place of selective serotonin reuptake inhibitors (ssris) in the treatment of depressive disorders in children and adolescents. |
2024-02-13 |
2024-02-15 |
Not clear |
| Ethan A Poweleit, Samuel E Vaughn, Zeruesenay Desta, Judith W Dexheimer, Jeffrey R Strawn, Laura B Ramse. Machine Learning-Based Prediction of Escitalopram and Sertraline Side Effects with Pharmacokinetic Data in Children and Adolescents. Clinical pharmacology and therapeutics. 2024-02-01. PMID:38297828. |
selective serotonin reuptake inhibitors (ssri) are the first-line pharmacologic treatment for anxiety and depressive disorders in children and adolescents. |
2024-02-01 |
2024-02-03 |
Not clear |
| Mehdi Sekssaoui, Joël Bockaert, Philippe Marin, Carine Bécame. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-01-11. PMID:38212441. |
antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-ht major depressive disorder (mdd) is one of the most disabling psychiatric disorders in the world. |
2024-01-11 |
2024-01-14 |
mouse |
| Vanessa K Tassone, Fatemeh Gholamali Nezhad, Ilya Demchenko, Alice Rueda, Venkat Bha. Amygdala biomarkers of treatment response in major depressive disorder: An fMRI systematic review of SSRI antidepressants. Psychiatry research. Neuroimaging. vol 338. 2024-01-06. PMID:38183847. |
functional neuroimaging studies have demonstrated abnormal activity and functional connectivity (fc) of the amygdala among individuals with major depressive disorder (mdd), which may be rectified with selective serotonin reuptake inhibitor (ssri) treatment. |
2024-01-06 |
2024-01-09 |
Not clear |
| Susan J Kea. Gepirone Extended-Release: First Approval. Drugs. 2023-12-11. PMID:38079093. |
gepirone hcl extended-release (gepirone er; exxua™), an oral, selective serotonin (5ht)1a receptor agonist formulated for once-daily administration, has been developed by fabre-kramer pharmaceuticals, inc. for the treatment of psychiatric disorders, including major depressive disorder (mdd). |
2023-12-11 |
2023-12-17 |
Not clear |
| Elena V Mitroshina, Ekaterina A Marasanova, Maria V Vedunov. Functional Dimerization of Serotonin Receptors: Role in Health and Depressive Disorders. International journal of molecular sciences. vol 24. issue 22. 2023-11-25. PMID:38003611. |
functional dimerization of serotonin receptors: role in health and depressive disorders. |
2023-11-25 |
2023-11-28 |
Not clear |
| Elena V Mitroshina, Ekaterina A Marasanova, Maria V Vedunov. Functional Dimerization of Serotonin Receptors: Role in Health and Depressive Disorders. International journal of molecular sciences. vol 24. issue 22. 2023-11-25. PMID:38003611. |
alterations in dimerization capacity can influence the functional characteristics of serotonin receptors and may constitute a contributing factor to the onset of depressive disorders. |
2023-11-25 |
2023-11-28 |
Not clear |
| Naomichi Okamoto, Takashi Hoshikawa, Yuichi Honma, Enkhmurun Chibaatar, Atsuko Ikenouchi, Masaru Harada, Reiji Yoshimur. Effect modification of tumor necrosis factor-α on the kynurenine and serotonin pathways in major depressive disorder on type 2 diabetes mellitus. European archives of psychiatry and clinical neuroscience. 2023-11-22. PMID:37991535. |
effect modification of tumor necrosis factor-α on the kynurenine and serotonin pathways in major depressive disorder on type 2 diabetes mellitus. |
2023-11-22 |
2023-11-29 |
Not clear |